About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk: London, UK Tuesday, May 19, 2026, 12:00 Hrs [IST] GSK plc announced tha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results